Elan

Elan Debt/EBITDA

The Total Debt to EBITDA Ratio of Elan (6099.T) as of Nov 2, 2026 is 0.18. In the previous year, Total Debt to EBITDA Ratio was 0.02 — a change of 648.78% (higher).

Debt/EBITDA

0.18

YoY

648.78%

Last updated:

Total Debt to EBITDA Ratio of Elan is 2025 0.18 . Total Debt to EBITDA Ratio of Elan was 2024 0.02 . It decreases by 648.78% higher compared to the previous year.

The Elan Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
0.00 JPY
Jan 1, 2019
0.00 JPY
Jan 1, 2020
0.00 JPY
Jan 1, 2021
0.00 JPY
Jan 1, 2022
0.00 JPY
Jan 1, 2023
0.00 JPY
Jan 1, 2024
0.02 JPY
Jan 1, 2025
0.18 JPY
The Elan Debt/EBITDA history
YEARDebt/EBITDAYoY
0.18+648.78%
0.02—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00-100.00%
0.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

Total Debt to EBITDA Ratio of Elan is 0.18 in 2025.

Total Debt to EBITDA Ratio of Elan changed from 0.02 to 0.18, representing a 648.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Elan since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Elan with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Elan

All Key Metrics — Elan